Publicaciones en colaboración con investigadores/as de Hospital Universitario Puerta del Mar (33)

2024

  1. Embolization of percutaneous left atrial appendage closure devices: timing, management and clinical outcomes

    Cardiovascular Revascularization Medicine

2023

  1. Clinical, Histopathologic and Genetic Features of Rhabdoid Meningiomas

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  2. Coronary Obstruction After Transcatheter Aortic Valve Replacement: Insights From the Spanish TAVI Registry

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 10, pp. 1208-1217

  3. Spontaneously ruptured hepatocellular carcinoma on non-cirrhotic liver: A prospective case series

    Gastroenterologia y Hepatologia

  4. Transcatheter aortic valve implantation in patients with extra-small aortic annuli

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 19, Núm. 4, pp. e340-e351

2022

  1. Early clinical outcomes after transaxillary versus transfemoral TAVI. Data from the Spanish TAVI registry

    Revista Espanola de Cardiologia, Vol. 75, Núm. 6, pp. 479-487

  2. Impact of operatoŕs experience on peri-procedural outcomes with Watchman FLX: Insights from the FLX-SPA registry

    IJC Heart and Vasculature, Vol. 38

  3. Management and outcomes of patients with left atrial appendage thrombus prior to percutaneous closure

    Heart (British Cardiac Society), Vol. 108, Núm. 14, pp. 1098-1106

  4. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial

    European Journal of Heart Failure, Vol. 24, Núm. 3, pp. 581-588

2021

  1. A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure

    Frontiers in Physiology, Vol. 12

  2. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

    BMC Infectious Diseases, Vol. 21, Núm. 1

  3. Consequences of canceling elective invasive cardiac procedures during Covid-19 outbreak

    Catheterization and Cardiovascular Interventions, Vol. 97, Núm. 5, pp. 927-937

  4. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

    PLoS ONE, Vol. 16, Núm. 9 September

  5. Impact of diabetes in patients waiting for invasive cardiac procedures during COVID-19 pandemic

    Cardiovascular Diabetology, Vol. 20, Núm. 1

2020

  1. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients

    Rheumatology (Oxford, England), Vol. 59, Núm. 12, pp. 3906-3916

  2. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience

    Revista Espanola de Cardiologia, Vol. 73, Núm. 12, pp. 994-1002

  3. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

    Haematologica, Vol. Online ahead of print

  4. Prevalence, clinical profile and prognostic implications of interatrial block in patients admitted for heart failure

    REC: CardioClinics, Vol. 55, Núm. 3, pp. 155-164

2019

  1. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

    Cancer Medicine, Vol. 8, Núm. 16, pp. 6955-6966

2018

  1. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

    British Journal of Haematology, Vol. 181, Núm. 3, pp. 350-359